Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of the HDAC Inhibitor LBH589 in Combination With the mTOR Inhibitor RAD001 in Metastatic Renal Cell Carcinoma

Next Previous
X
Search
Trial Profile

A Phase I/II Study of the HDAC Inhibitor LBH589 in Combination With the mTOR Inhibitor RAD001 in Metastatic Renal Cell Carcinoma

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Panobinostat (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 25 Oct 2019 According to the results published in the Investigational New Drugs, the first 2 patients at dose level 2 experienced dose-limiting thrombocytopenia (grade 3 and grade 4), and the dose was de-escalated back to dose level 1. The next 10 patients enrolled at dose level 1 did not experience a DLT, so the protocol was amended to introduce an intermediate dose level 1A that followed an alternate dose-escalation model.
    • 25 Oct 2019 Results assessing the expression of microRNA 605 (miR-605) in serum samples of the patients, published in the Investigational New Drugs
    • 15 Jul 2016 Status changed from active, no longer recruiting to discontinued as pts off study and PI left institute.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top